The authors reply

Critical Care Medicine www.ccmjournal.org e797 increased production of angiotensin II seems to drive the occurrence of kidney injury, and RAS inhibitors could block the physiologic effect of angiotensin II (5). Therefore, we urge the performance of clinical trials to investigate the potential protective effects of RAS inhibitors against the development of acute kidney injury in patients with COVID-19.

[1]  C. S. Kow,et al.  Can Renin-Angiotensin System Inhibitors Protect Against Acute Kidney Injury in Patients With COVID-19? , 2022, Critical care medicine.

[2]  Arthur S Slutsky,et al.  Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19* , 2022, Critical care medicine.

[3]  P. Stenvinkel,et al.  Angiotensin‐converting enzyme 2 and transmembrane protease serine 2 in female and male patients with end‐stage kidney disease , 2022, European journal of clinical investigation.

[4]  Lisa H. Merck,et al.  Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury , 2022, JAMA network open.

[5]  M. M. Mata-Miranda,et al.  ACE and ACE2 Gene Variants Are Associated With Severe Outcomes of COVID-19 in Men , 2022, Frontiers in Immunology.

[6]  Tales,et al.  COVID-19-associated acute kidney injury patients treated with renal replacement therapy in the intensive care unit: A multicenter study in São Paulo, Brazil , 2022, PloS one.

[7]  G. Oudit,et al.  Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries , 2021, Hypertension.

[8]  D. Casarini,et al.  Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients , 2021, Frontiers in Physiology.

[9]  F. Pelorosso,et al.  Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial , 2021, EClinicalMedicine.

[10]  R. Kullar,et al.  Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia , 2021, Infectious Diseases and Therapy.

[11]  R. Zand,et al.  Comparison of losartan and amlodipine effects on the outcomes of patient with COVID‐19 and primary hypertension: A randomised clinical trial , 2021, International journal of clinical practice.

[12]  C. Granger,et al.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[13]  T. Chang,et al.  Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial , 2021, The Lancet Respiratory Medicine.

[14]  S. Murthy,et al.  Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis , 2021, Canadian journal of kidney health and disease.

[15]  Samantha K. Brenner,et al.  AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[16]  C. S. Kow,et al.  Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury. , 2020, Journal of the American Society of Nephrology : JASN.

[17]  Victor G. Puelles,et al.  Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.

[18]  Cheng Wan,et al.  Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China , 2020, Kidney International.